NMP had no intrinsic antibacterial activity against clinical isolates at the concentration used in the MIC reduction experiments Table 1 ; . NMP at a concentration of 25 mg L had no or minor effects on the MICs of the test drugs, whereas PAbN at this concentration reduced the MICs of linezolid, clarithromycin and rifampicin by 4-fold or more in the majority of clinical isolates irrespective of whether they were fluoroquinolone-resistant or fluoroquinolone-susceptible Table 2 ; . At this concentration PAbN had rather limited effects on fluoroquinolone MICs in E. coli, a finding consistent with a report by Saenz et al.10 Using ciprofloxacin instead of levofloxacin did not improve the capacity of PAbN to reverse fluoroquinolone resistance data not shown ; . Particularly strong effects with PAbN at 25 mg L were seen with clarithromycin and, surprisingly, with rifampicin.
NATIONAL ASSOCIATION FOR STOCK CAR AUTO RACING, INC. FLORIDA CORPORATION ; KAREN B. LEETZOW 1801 W. INTERNATIONAL SPEEDWAY BLVD. DAYTONA BEACH, FL 32114 FOR: CHARITABLE FUND RAISING SERVICES, IN CLASS 36 U.S. CLS. 100, 101 AND 102. With regard to PC, GEM is currently the most promising new agent being tested. An early phase II trial in patients with advanced PC revealed a lower tumor response rate, but frequent subjective symptomatic improvement clinical benefit response ; was observed, often in the absence of a tumor response 19 ; . Based on these observations, two subsequent trials of GEM were initiated, in which clinical benefit response was employed as the primary end-point 9, 10 ; . In the randomized trial comparing GEM with 5-fluorouracil 5-FU ; , GEM therapy showed significantly better results in clinical benefit response rates and survival 10 ; . Moreover, the phase II trial in patients with 5-FU-refractory PC also demonstrated similar effects on disease-related symptoms 9 ; . Accordingly, GEM has been accepted as first-line chemotherapy for PC in Western countries. In these trials, GEM at a dose of 1000 mg m2 was administered seven times followed by 1 week of rest and then GEM three times every 4 weeks thereafter. In the present trial, 11 chemo-naive patients with metastatic PC were treated weekly with GEM 1000 mg m2 ; to confirm the tolerability of this dose schedule in Japanese patients with advanced PC. Hematological toxicity, particularly leukocytopenia and or neutropenia, was the most common severe toxicity of GEM with this schedule, although non-hematological toxicities were mild and well tolerated. There was no DLT observed in Schedule 1, but two of six evaluable patients showed DLT in Schedule 2. With regard to anti-tumor activity of GEM, two patients achieved a partial response, giving an overall response rate of 18%. Moreover, two 27% ; of the seven eligible patients achieved a clinical benefit response. These findings regarding toxicity and anti-tumor effect of GEM therapy were consistent with those of previous trials using the same dose schedule of GEM. Consequently, in Japanese patients with PC, further trials of GEM can be conducted with Schedule 2. The previous phase I trial conducted in Japan demonstrated that the recommended dose schedule of GEM was 800 mg m2 weekly 3 followed by 1 week of rest, with leukocytopenia as DLT 20 ; . However, the current trial may indicate that Schedule 2 1000 mg m2 GEM weekly 7 followed by a week of rest and then GEM 3 every 4 weeks thereafter ; may be tolerated in patients with advanced PC. The reason for the different results remains to be elucidated, although a once weekly schedule for seven consecutive weeks had not been tested in the previous trial. The differences in patient characteristics such as performance status and a history of chemotherapy between these two trials are the most likely explanation for this inconsistency. Only chemo-naive patients had been enrolled and all had a good KPS of 80 points in our trial, while 11 39% ; of 28 patients had a poor performance status of 23 and 23 patients 82% ; had a history of chemotherapy in the previous phase I trial. In conclusion, GEM 1000 mg m2 weekly 7 followed by a week of rest and weekly 3 every 4 weeks thereafter may be tolerated in Japanese patients with advanced PC.

Background. The choice of post-remission treatment for patients with acute myeloid leukemia AML ; in first remission CR1 ; is controversial. Toxicity of transplant procedures are a maijor draw back. Aim of the study. To test the outcome of patients with AML in CR1 undergoing an allogeneic bone marrow transplant BMT ; in our Unit in the past 20 years.Patients. We analyzed 170 patients with AML in first complete remission, aged 1-47 years median 29 ; , undergoing an allogeneic bone marrow transplant BMT ; 1990 n 80 and n 90 respectively all patients were prepared with cyclophosphamide, total body irradiation TBI the median follow up for surviving patients is 13 years. The donor was an HLA identical sibling in 164 patients. Results. Transplant related mortality TRM ; was 30% before, and 7% after 1990 p 0.001 relapse related death RRD ; 26% and 11% p 0.002 actuarial 10 year survival 42% and 79% p 0, 00001 ; . Patients transplanted after 1990 were older, had a shorter interval diagnosis-BMT, had less FAB-M3 cases, received a higher dose of TBI, a higher marrow cell dose and combined cyclosporine + methotrexate ; graft vs host disease GvHD ; prophylaxis. Patients relapsing after transplant had an actuarial survival of 0% vs 31% if grafted 1990 p 0.01 ; , and their median follow up exceeds 10 years. Conclusions. The overall survival of first remission AML undergoing an allogeneic BMT has almost doubled in the past two.

Figure 1. Study schema. a ; Cy 60 mg kg per day, TBI total dose 13.2 Gy, fractionated as 165 cGy twice daily for 4 days; b ; busulfan 1 mg kg per dose given 4 times daily, Cy 60 mg kg per day; c ; GVHD prophylaxis: cyclosporine A in the Cy TBI group ; or cyclosporine A or tacrolimus in the Bu Cy group ; starting day 3 in combination with methotrexate 15 mg m2, IV bolus on day 1 and methotrexate 10 mg m2, IV bolus on days 3, 6, and 11; d ; filgrastim 5 g kg per day from 24 hours after transplantation until neutrophil recovery absolute neutrophil count [ANC], 1 109 L for 3 consecutive days, or 10 109 L for 1 day, whichever occurred first ; . K40 indicates palifermin 40 g kg per day; K60, palifermin 60 g kg per day; P, placebo; Cy, cyclophosphamide; Bu, busulfan; RT, radiotherapy and cytomel.